BioInvent International AB: Interim Report January – June 2025

Summary by AI BETAClose X

BioInvent announced strategic portfolio changes to accelerate clinical programs and enhance value creation. Second quarter 2025 net sales reached SEK 198.1 million, a significant increase from SEK 4.6 million in the previous year. The company reported a profit after tax of SEK 38.8 million, a substantial improvement compared to a loss of SEK 137.3 million. Profit per share was SEK 0.59, up from a loss of SEK 2.09. Cash flow from operating activities was SEK 66.8 million, compared to negative SEK 119.2 million. Liquid funds, current and long-term investments totaled SEK 797.5 million, down from SEK 1,090.3 million. XOMA purchased mezagitamab royalty and milestone rights for up to USD 30 million.

Disclaimer*

UK 100

Latest directors dealings